Showing results (201-210 of 219) with videos related to
Sort By:
Pageof 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2021
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE StudyWilliam G Wierda, John N Allan, Tanya Siddiqi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2024
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective StudyAdam S Kittai, David Bond, Ying Huang, et al.Cancer Cell|September 22, 2023
ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndromeErin M Parry, Camilla K Lemvigh, Stephanie Deng, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826Sarah C Rutherford, Hongli Li, Alex F Herrera, et al.Cancer|November 25, 2024
Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemiaWei-Ying Jen, Jennifer Marvin-Peek, Hagop M Kantarjian, et al.Human Gene Therapy|April 30, 2014
Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013Marina O'Reilly, Howard J Federoff, Yuman Fong, et al.British Journal of Haematology|November 5, 2019
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemiaToby A Eyre, Lindsey E Roeker, Christopher P Fox, et al.The Journal of Clinical Investigation|August 3, 2016
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cellsPartow Kebriaei, Harjeet Singh, M Helen Huls, et al.Lancet (London, England)|July 9, 2026
Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trialMatthew S Davids, Toby A Eyre, Jennifer A Woyach, et al.American Journal of Hematology|August 23, 2018
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trialAnthony R Mato, Lindsey E Roeker, John N Allan, et al.Pageof 22